Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
18 Octobre 2023 - 2:30PM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”) announced the appointments of Bruce Cassidy and John
Gandolfo to the Board of Directors effective October 4, 2023.
“We are delighted to welcome Bruce Cassidy and John Gandolfo to
the Oragenics Board,” said Charlie Pope, Chairman of Oragenics.
“Bruce’s deep experience in high-technology global businesses will
be invaluable to Oragenics as we grow our portfolio. John’s proven
leadership in the life sciences, capital raising and financial
management will be critical to our future. We are confident that
Bruce and John will provide valuable perspectives as we continue to
execute our strategy, pursue our mission to serve patients and
enhance value for all Oragenics’ shareholders.”
Mr. Cassidy currently serves on the boards for various
companies, including as Chairman of the Board of each of Loop
Media, Inc., KeyStar Corp, Arboreta Healthcare, Inc., Selinsky
Force, LLC and The Sarasota Green Group. He was also the founding
investor and served on the board of directors of Ohio Legacy Corp.
Previously, Mr. Cassidy was the founder and Chief Executive Officer
(CEO) of Excel Mining Systems from 1991 until its sale in 2007 to
Orica Mining Services, and from 2008 to 2009, served as the
President and CEO of one of its subsidiaries, Minova North &
South Americas. He is currently the President of The Concession
Golf Club in Sarasota, Florida.
“I am excited to be a part of the next generation of drug and
delivery technologies for critical unmet medical needs. The unique
platform of formulas and the nasal application of delivering novel
therapeutics represents the future of neurological drugs. I look
forward to working with the Oragenics Board and the Odyssey team to
help steer the new strategy and direction of the Company,” said
Bruce Cassidy.
Mr. Gandolfo has more than 30 years of experience as a Chief
Financial Officer (CFO) of multiple rapidly growing private and
publicly held companies with a primary focus in the life sciences,
healthcare and medical device areas. Mr. Gandolfo has had direct
responsibility over all financial and treasury functions including
capital raising and mergers and acquisitions. Mr. Gandolfo
currently serves as CFO of Eyenovia, Inc., (EYEN) a late-stage
ophthalmic biopharmaceutical company since January 2018. Prior to
this, Mr. Gandolfo was CFO of Xtant Medical Holdings, Inc., a
biologics company, from July 2010 through September 2017. Prior to
this, he served as the CFO for Progenitor Cell Therapy LLC from
January 2009 to June 2010 and, before that, as CFO of Power Medical
Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo
currently serves on the Board of Directors of Electrocore, Inc.
(ECOR) and previously served on the Board of Directors and was
chair of the Audit Committee of Odyssey Health, Inc. f/k/a Odyssey
Group International, Inc., (ODDY) from 2019 until 2023. Oragenics
announced the signing of an asset purchase agreement with Odyssey
Health on October 6, 2023.
“Having been involved with the Odyssey team for the past few
years I am a strong believer in the technology and the synergies
with Oragenics. I am happy to continue my involvement as a member
of Oragenics Board,” said John Gandolfo.
Mr. Gandolfo is currently a member of the Board of Directors of
Electrocore, Inc. (ECOR) and is chair of the Compensation Committee
and sits on their audit committee. Mr. Gandolfo received his B.A.
degree in Business Administration from Rutgers University.
About Oragenics
Oragenics, Inc. is a development-stage company focused on nasal
delivery of pharmaceutical medications including in neurology and
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. Its lead product is NT-CoV2-1, an
intranasal vaccine candidate to prevent COVID-19 and variants of
the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus
spike protein research licensed from the National Institutes of
Health (NIH) and the National Research Council of Canada (NRC) with
a focus on reducing viral transmission and offering a more
patient-friendly intranasal administration. Its lantibiotics
program features a novel class of antibiotics against bacteria that
have developed resistance to commercial antibiotics. For more
information, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding: the ability of Odyssey and
Oragenics to successfully close their asset purchase agreement; the
ability of the Oragenics to timely and successfully achieve the
anticipated benefits of acquiring the Odyssey assets; Oragenics’
future performance, business prospects, events and product
development plans. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “project” and similar expressions that do not relate
solely to historical matters identify forward-looking statements.
Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to, the
following: Oragenics’ ability increase its authorized shares of
Common Stock; Oragenics’ ability to obtain a quorum at future
shareholders meetings; Oragenics’ ability to obtain its
shareholders’ approval for the (a) the increase in Oragenics’
authorized Common Stock from 4,166,666 to 350,000,000 and (b) the
conversion of the Series F Preferred Stock into Common Stock;
whether or not all of the closing conditions to the Odyssey
transaction will be satisfied and otherwise whether Oragenics will
be able to successfully close the Odyssey transaction; Oragenics’
ability to obtain necessary funding, non-dilutive or otherwise, for
the development of its product candidates, including its vaccine
and lantibiotic assets and, if the Odyssey transaction successfully
closes, the concussion asset; Oragenics’ ability to advance the
development of its vaccine candidate and lantibiotics candidate
(and, if the Odyssey transaction successfully closes, the
concussion asset) under the timelines and in accord with the
milestones it projects; the regulatory application process,
research and development stages, and future clinical data and
analysis relating to vaccines and lantibiotics, including any
meetings, decisions by regulatory authorities, such as the FDA and
Canadian regulatory authorities and investigational review boards,
whether favorable or unfavorable; the potential application of
Oragenics’ vaccine candidate to variants and other coronaviruses;
Oragenics’ ability to obtain, maintain and enforce necessary patent
and other intellectual property protection and license agreements;
the nature of competition and development relating to COVID-19
immunization and therapeutic treatments and demand for vaccines and
antibiotics; Oragenics’ and/or Odyssey’s expectations as to the
outcome of preclinical studies, nasal administration, transmission,
manufacturing, storage and distribution; other potential adverse
impacts such as delays in regulatory review, manufacturing delays
and supply chain issues, adverse impacts on healthcare systems and
disruption of the global economy; the ability to sustain compliance
with Oragenics’ exchange listing requirements; and general economic
and market conditions and risks, as well as other uncertainties
described in our filings with the U.S. Securities and Exchange
Commission. All information set forth in this press release is as
of the date hereof. You should consider these factors in evaluating
the forward-looking statements included in this press release and
not place undue reliance on such statements. We do not assume any
obligation to publicly provide revisions or updates to any
forward-looking statements, whether as a result of new information,
future developments or otherwise, should circumstances change,
except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231018301092/en/
Oragenics, Inc. Janet Huffman, Chief Financial Officer
813-286-7900 jhuffman@oragenics.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024